CAMBRIDGE, Mass. – eGenesis, a biotechnology company focused on developing human-compatible engineered organs to address the global organ shortage, has appointed Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its board of directors.
Williams brings more than three decades of leadership in the biopharmaceutical sector, having held senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics (now Seagen). His career includes contributions to the development of several major therapies such as Enbrel®, Tecfidera®, and Spinraza®. Most recently, he was President of R&D at Sana Biotechnology and the founding CEO of Codiak Biosciences. He currently chairs the board of Climb Bio and serves on the board of CAMP4 Therapeutics.
Craig has more than 25 years of experience in global drug development and commercialization, particularly in oncology, hematology, and rare diseases. He previously served as President and CEO of CTI BioPharma, where he led the approval and commercialization of Vonjo®. He is now Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). His earlier career includes senior development positions at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals. Craig also serves on the board of Stratus Therapeutics. A Member of the Royal College of Physicians in the U.K., he holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School.
“Doug and Adam are highly accomplished leaders whose deep expertise across R&D, commercialization, and corporate strategy will be invaluable as we advance our development candidates, EGEN-2784 for kidney failure and EGEN-5784 for liver failure, into the clinic,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis. “Their guidance will be invaluable as we advance into the next phase of growth as a clinical-stage company focused on our mission to transform the treatment of organ failure.”
“eGenesis is developing truly pioneering solutions for one of the most pressing unmet needs in medicine,” said Williams. “The combination of cutting-edge genetic engineering, rigorous science, and a mission-driven team positions eGenesis to deliver breakthroughs that could fundamentally change the field of organ transplantation.”
“eGenesis is leading a field with the potential to transform the future of transplantation,” added Craig. “I look forward to supporting the company’s mission to develop safe, effective, human-compatible organs that could redefine the treatment of organ failure and offer hope to millions of patients awaiting a transplant.”
Williams and Craig join the current board of directors, which includes Chairman Steven Gillis, Ph.D., Bob More, Fabio Pucci, Ph.D., Brad Smith, Julie Sunderland, and Albert (Al) Wiegman.
